Kornimate/medical-research-clean huggingface dataset:
acupuncture for the treatment of post-traumatic stress disorder (ptsd)

Conditions: Stress Disorders, Post-Traumatic

Summary: the purpose of this study is to evaluate acupuncture as a treatment for post-traumatic stress disorder (ptsd) and to correlate the diagnosis of ptsd with traditional chinese medicine (tcm) diagnostic patterns.

this study will evaluate: 1) the tcm diagnostic differentiation patterns of people who have ptsd as defined by the diagnostic and statistical manual, 4th edition; 2) if an acupuncture treatment approach is acceptable to people with ptsd; and 3) if an acupuncture treatment approach is associated with a reduction in ptsd symptoms that is comparable to that of standard treatments. because symptoms of depression, insomnia, and pain are often associated with ptsd, we will also evaluate the potential benefit of an acupuncture approach to depression, insomnia, and pain symptoms in people with ptsd. patients in this study will be randomized to one of three groups. group a will receive acupuncture therapy. group b will receive standard cognitive behavior therapy. group c is a control group and will receive no treatment. patients in groups a and b will undergo a total of 24 hours of therapy over the 3 month study course. all patients will have five nontherapeutic study visits; these visits will address diagnosis and assessment. study visits will include assessments of ptsd symptoms, sleep symptoms, and level of impairment.

Eligibility criteria:
inclusion criteria * dsm-iv diagnosis of ptsd * stage i ptsd symptoms * ptsd symptom scale-self report (pss-sr) score \> 16 * meets pss-sr diagnostic criteria exclusion criteria * stage i substance abuse and/or dependence in the past 6 months * psychotic disorder * inability to commit to treatment or wait-list conditions * current treatment specifically for ptsd * certain medical conditions, including thyroid disease, class iv heart failure, active cancer treatment, and uncontrolled diabetes * pregnant * use of benzodiazepines, narcotics, opiates, narcotic antagonists, sleep medication, muscle relaxants, analgesics, or sedatives.

Keywords: acupuncture medicine, chinese traditional
cold atmospheric plasma device for pediatric molluscum and verruca

Conditions: Verruca Vulgaris; Molluscum Contagiosum Skin Infection

Summary: this study is going to test a cold atmospheric plasma device (cap), in particular a floating electrode-dielectric barrier device (fe-dbd), to treat warts and molluscum. the treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. based on the successes of previous dermatologic studies, fe-dbd is being tested for this study to treat warts and molluscum. patients will be enrolled to test the efficacy and safety of this device. the duration of the study is 4-12 weeks depending on treatment clearance. the number of lesions will be chosen by the dermatologist. patients will receive standard of care therapy and/or ntap depending on the number of lesions.


Eligibility criteria:
inclusion criteria: * all patients from 4-21 years old with at least 1 lesion of either verruca vulgaris or molluscum contagiosum * willingness of the participant and their guardian to provide consent when applicable exclusion criteria: * unwillingness to participate in the study * received any treatment on the lesion in the past month, as determined by review of participant medical record * immunodeficiency as determined by review of participant medical record * adverse response to prior treatments as determined by review of medical record * signs of self-resolution as determined by study team members * conditions that lead to excessive scarring as determined by study team members * facial and genital lesions as determined by study team members

Keywords: plasma cryotherapy pediatrics warts molluscum dermatology cantharidin
home monitoring for atrial fibrillation using a microlife blood pressure monitor

Conditions: Atrial Fibrillation

Summary: this study assess the accuracy of a blood pressure monitor designed to detect atrial fibrillation. subjects use the blood pressure monitor on a daily basis for 30 days and compare the readings to an ecg done at the same time.


Eligibility criteria:
inclusion criteria: any of the following * age 65 or older * hypertension * diabetes mellitus * congestive heart failure * previous stroke exclusion criteria: * permanent pacemaker * impalantable defibrillator

Keywords: atrial fibrillation home blood pressure monitoring
pk of piperacillin/tazobactam in adults undergoing ecmo

Conditions: Acute Respiratory Failure With Hypoxia

Summary: this study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ecmo). the investigators hypothesize that patients will have significant changes in concentration measurements, specifically an increased clearance rate and increased volume of distribution, during ecmo as compared to critically ill patients.

in a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. however, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply blood with oxygen. in this case, patients may require assistance from a machine to help provide this oxygen. extracorporeal membrane oxygenation (ecmo) is a device that acts as an artificial lung, allowing the patient to recover from their illness. patients receiving support from ecmo are often put in a medically induced coma while their lungs heal. certain drugs may stick to the internal surfaces of the machine; therefore leading to decreased concentrations. patients receiving ecmo often require antimicrobials to treat severe infections. however, little data exist concerning the likely changes in drug concentrations from drug circuit interactions in adult patients receiving ecmo.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * initiated on vv ecmo for acute respiratory distress syndrome * receiving piperacillin/tazobactam exclusion criteria: * pregnancy * massive blood transfusion (10 units or more of of prbc) within a 24-hour period * prisoners

Keywords: ecmo antimicrobials
population pharmacokinetics of linezolid

Conditions: Methicillin-Resistant Staphylococcus AureuS

Summary: linezolid is the first of a new class of antibacterial drugs, the oxazolidinones. it has a specific inhibitory activity against gram positive bacteria, including methicillin-resistant staphylococcus aureus (mrsa). dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers. the intensive care units patients, with mechanical ventilation, and with severe sepsis, represent highly heterogeneous population responsible of hight variability in pharmacokinetics parameters (augmentation in total volume of distribution, modification in glomerular filtration) wich can lead to antibiotic inefficacy. in a first time, this study describe the pharmacokinetics of linezolid in intensive care units patients with severe mrsa infection. the aim of this study is to define and validate a population pharmacokinetic model including the influence of patients' characteristic on the pharmacokinetics of linezolid.

the demographic, clinical and biological parameters are collected. patients receive linezolid as 600 mg twice a day during an administration of 60 minutes. blood sampling are collected on the second day after beginning of treatment at the following time : h1, h2, h3, h6 and h12. the population pharmacokinétics analysis will be carried out using monolix, a software for the analysis of nonlinear mixed effects models.

Eligibility criteria:
inclusion criteria: * in-patient stay in intensive care * over 18 years old * presenting with mrsa nosocomial pneumonia or bacteraemia with a strain thought to be sensitive to linezolid * simplified acute physiological score (saps) ii \> 20 * expected duration of life \> 7 days. exclusion criteria: * history of allergy to linezolid or any of the antibiotics used * isolation of mrsa resistant to linezolid * lack of seeds * pregnancy and lactation

Keywords: population pharmacokinetics linezolid monolix nonlinear mixed effects models
working memory training in children with cerebral palsy, a pilot study

Conditions: Cerebral Palsy; Working Memory Training

Summary: the purpose of this pilot study is to assist the preparation of a larger multi-center study. the main aim is to determine the feasibility of conducting computerized working memory training in a group of children with cerebral palsy.


Eligibility criteria:
inclusion criteria: * born at term with unilateral spastic cp * born preterm with bilateral spastic cp exclusion criteria: * children with gross motor function classification scale (gmfcs) level v * severe visual or hearing impairments * photosensitive epilepsy
bimatoprost in the treatment of eyelash hypotrichosis

Conditions: Idiopathic Eyelash Hypotrichosis

Summary: this study will evaluate the safety and efficacy of bimatoprost solution formulation a compared with bimatoprost solution 0.03% (latisse®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).


Eligibility criteria:
inclusion criteria: -male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth). exclusion criteria: * damage to eyelid area (scarring) that may prevent growth of eyelashes * active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye) * eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening * current eyelash implants of any kind * eyelash tint or dye application within 2 months of baseline * eyelash extensions application within 3 months of baseline * use of eyelash growth products within 6 months of baseline * treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.
flecainide for catecholaminergic polymorphic ventricular tachycardia

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia

Summary: the purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with catecholaminergic polymorphic ventricular tachycardia.

catecholaminergic polymorphic ventricular tachycardia (cpvt) is a genetic arrhythmia syndrome characterized by frequent ventricular ectopy and polymorphic, classically bidirectional ventricular tachycardia with physical or emotional stress, which also carries a risk of ventricular fibrillation and sudden death, despite no structural heart abnormality. treatment consists of beta-blockers and/or calcium channel blockers, but up to 30% of patients require implantable cardioverter-defibrillators (icds) due to recurrent symptoms on medical therapy. in an animal model, flecainide was found to directly target the molecular defect in cpvt. in a retrospective clinical study in patients with cpvt we have seen improvement of ventricular ectopy on exercise tests when flecainide is added to standard therapy. we propose a prospective trial of flecainide added to standard therapy in cpvt patients to test the hypothesis that flecainide will reduce ventricular ectopy on exercise testing compared to placebo plus standard therapy. this will be a single-blind (blinded subjects) randomized cross-over study, in which each patient will receive treatment a (flecainide or placebo) for at least 3 months and, after a 1 week wash-out, treatment b (placebo or flecainide) for at least 3 months.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of cpvt, based on: a. reproducible polymorphic or bidirectional ventricular tachycardia with exercise or b. ventricular ectopy on exercise test with ryr2 or casq2 mutation 2. functioning icd in place 3. on stable dose of standard therapy defined as the maximal tolerated dose of beta-blocker and may include a calcium channel blocker patients on flecainide or mexiletine are also eligible for enrollment after a 1 week "washout" period during which flecainide or mexiletine is discontinued, and standard therapy alone is used. exclusion criteria: 1. females who are pregnant or plan to be pregnant during the study period 2. children \< 5 years of age 3. patients unable to perform treadmill exercise 4. patients with significant structural heart disease 5. patients with features consistent with andersen-tawil syndrome a. periodic paralysis or unexplained weakness b. dysmorphic facies c. known kcnj2 mutation 6. patients with known hypersensitivity to flecainide 7. patients on amiodarone 8. patients not expected to comply with follow-up

Keywords: catecholaminergic polymorphic ventricular tachycardia implantable cardioverter-defibrillator flecainide
a multicenter observational study of invasive candida infections among icu patients in china

Conditions: Candidiasis

Summary: the incidence of invasive candida infection (ici) in critically ill patients is increasing day by day. the crude mortality of ifi in icu could be as high as 25%-75% depending on their age, underlying conditions, and so on. candida albicans was by far the predominant species in most countries, causing up to two thirds of all cases of invasive candidiasis. however, a shift toward non-albicans candida species has been observed. although the studies of ici cause universal attention recently, there is still no large-scale, multi-center epidemiological research in china focusing on ici in critically ill patients, therefore we conducted a large-scale multi-center observational study of ifi in critically ill patients named "china scan" (china survey of candidiasis in icu) to assess the current incidence, mortality, pathogen spectrum, management, and risk factors for ici in china icus.

background of the study: the incidence of invasive candida infection (ici) in critically ill patients is increasing day by day. the crude mortality of ici in icu could be as high as 25%-75% depending on their age, underlying conditions, and so on. candida albicans was by far the predominant species in most countries, causing up to two thirds of all cases of invasive candidiasis. however, a shift toward non-albicans candida species has been observed. although the studies of ici cause universal attention recently, there is still no large-scale, multi-center epidemiological research in china focusing on ifi in critically ill patients, therefore we conducted a large-scale multi-center observational study of ifi in critically ill patients named "china scan" (china survey of candidiasis in icu) to assess the current incidence, mortality, pathogen spectrum, management, and risk factors for ici in china icus. objective of the study: determine the current incidence of ifi in icus in china. describe the risk factors for ifi in china icus. explore the pathogen spectrum of ifi in icus in china. describe the in vitro antifungal susceptibility of candida isolates. describe the antifungal treatment for icu patients with ifi. evaluate in-hospital mortality among patients with ifi in icus.

Eligibility criteria:
inclusion criteria: -adult icu patients above 18 with ici- exclusion criteria: -non ici-

Keywords: invasive candida infection
study of a self-help depression skills program for college-aged youth

Conditions: Depression

Summary: we propose to conduct a pilot trial of an internet-only depression skills training program for adolescents and young adults. the intervention, moodhelper.org already exists and has been tested in two pilots. in this third pilot, we plan to use an enriched minority sampling frame to mail 3,000 to 6,000 invitational brochures to kpnw members aged 14 to 24, with a enrollment target of 150. interested members will go to the study internet site, and if they choose to participate, complete the online consent and assessment battery (used in the previous pilots). participants will be randomly assigned by the site's software to one of two conditions: (1) the "intervention" condition, with complete access to the sadhelper.org web site or (2) the "usual care" condition, with access to all internet sites and kpnw health care, but with no access to the therapeutic portion of the sadhelper site. all participants (those with and without access to the research intervention) will be reminded by e-mail and, if necessary, by telephone to return to the web site and complete follow-up questionnaires four, eight, sixteen, and thirty-two weeks after enrolling in the study.

we propose to conduct a pilot trial of an internet-only depression skills training program for adolescents and young adults. the intervention, moodhelper.org already exists and has been tested in two pilots. in this third pilot, we plan to use an enriched minority sampling frame to mail 3,000 to 6,000 invitational brochures to kpnw members aged 14 to 24, with a enrollment target of 150. interested members will go to the study internet site, and if they choose to participate, complete the online consent and assessment battery (used in the previous pilots). participants will be randomly assigned by the site's software to one of two conditions: (1) the "intervention" condition, with complete access to the sadhelper.org web site or (2) the "usual care" condition, with access to all internet sites and kpnw health care, but with no access to the therapeutic portion of the sadhelper site. all participants (those with and without access to the research intervention) will be reminded by e-mail and, if necessary, by telephone to return to the web site and complete follow-up questionnaires four, eight, sixteen, and thirty-two weeks after enrolling in the study.

Eligibility criteria:
inclusion criteria: current clinical diagnosis of depression internet access exclusion criteria: none
efficacy and safety study of ravulizumab iv in pediatric participants with nmosd

Conditions: Neuromyelitis Optica Spectrum Disorder

Summary: the primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with neuromyelitis optica spectrum disorder (nmosd).


Eligibility criteria:
inclusion criteria: * participants must be anti-aqp4 ab-positive and have a diagnosis of nmosd as defined by the 2015 international consensus diagnostic criteria. * complement inhibitor treatment-naïve participants must have had at least 1 attack or relapse in the last 12 months prior to the screening period. * expanded disability status scale (edss) score ≤ 7. * eculizumab-experienced participants must be clinically stable per investigator for 30 days and have been treated with eculizumab in study ecu-nmo-303 for at least 90 days prior to screening with no missed doses within 2 months prior to day 1. * participants who enter the study receiving supportive ist(s) (eg, corticosteroid, azathioprine \[aza\], mycophenolate mofetil \[mmf\], methotrexate \[mtx\], tacrolimus \[tac\], cyclosporin \[csa\], or cyclophosphamide \[cyc\]) for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration prior to screening and remain on a stable dosing regimen during the screening period. * to reduce the risk of meningococcal infection (neisseria meningitidis), all participants must be vaccinated against meningococcal infection. * documented vaccination for hib and s pneumoniae at least 14 days prior to day 1 according to national/local guidelines for the applicable age group. exclusion criteria: * use of rituximab within 3 months prior to screening. * currently treated with a biologic medications (other than eculizumab) that may affect immune system functioning, or has stopped treatment with a biologic medication that may affect immune system functioning, and 5 half lives of the medication have not elapsed by the time of the screening visit. * use of intravenous immunoglobulin (ivig) or plasma exchange (pe) within 3 weeks prior to screening. * participation in another investigational drug or investigational device study (other than study ecu-nmo-303) within 5 half lives of that investigational product (if known) or 30 days before initiation of the first dose of study drug, whichever is longer. * use of immunomodulatory therapies for multiple sclerosis within 3 months prior to screening.

Keywords: neuromyelitis optica spectrum disorder ravulizumab alxn1210 cns autoimmune disorders nmo nmosd
safety and effects of using prime-boost hivis dna and mva-cmdr vaccine regimens with or without toll-like receptor 4 agonist on hiv reservoirs in perinatally hiv infected children and youth

Conditions: HIV Infections

Summary: phase i, proof of concept, open-label, randomized clinical trial to evaluate the safety and effects of using prime-boost hivis dna and mva-cmdr vaccine regimens with or without toll-like receptor 4 agonist on hiv reservoirs in perinatally hiv infected children and youth

hivis dna and mva-cmdr vaccines induce immune responses important for clearing infected cells: broad hiv-specific cd8+ cytotoxic t cells, potent antibodydependent cellular cytotoxicity (adcc), and binding antibody (ab) and neutralizing antibody (nab). the study include early treated children because of their healthy immunity and small hiv reservoirs. giving licensed vaccine, cervarix®, against human papilloma virus (hpv) that contains toll-like receptor (tlr) 4 agonist with hivis dna could increase dna antigen loading on dendritic cells and promote adaptive immune responses to the hiv vaccine.

Eligibility criteria:
inclusion criteria: 1. hiv perinatally infected 2. know their hiv+ status 3. initiated art prior to 6 months of age 4. male and female ≥ 9 years old 5. in generally good health 6. plasma viral load \< 200 copies/ml on art at screening 7. cd4 count above 400 cells/mm3 at screening 8. participants of childbearing potential who are sexually active must be willing to practice effective contraception during the study 9. negative urine β-hcg (human chorionic gonadotropin) pregnancy test for any female of childbearing age (post-menarche) 10. availability for follow-up for planned duration of the study 11. passing a test of understanding is required for participants ≥ 18 years old or the parent(s)/legal representative of participants \< 18 years old before consent. 12. written informed consent from participants ≥ 18 years old or parent(s)/legal representative of participants \< 18 years old. assent by participants aged 9-17 years old will also be required. 13. laboratory criteria within 8 weeks prior to enrollment * hb \>11.0 g/dl * white blood cell count \>3000 cells/mm3 * platelets \>125,000/ mm3 * alt \<1.5 x upper limit of normal * creatinine \<1.5 x upper limit of normal exclusion criteria: 1. participants who experienced virological failure necessitating art modifications 2. participants who had art interruption that lasted \>2 weeks 3. prior or current pancreatitis or history of alcohol abuse. 4. systemic cortisone treatment within the past 30 days 5. participants coinfected with chronic hepatitis b (hepatitis b surface antigen, hbsag+) or hepatitis c (hepatitis c antibody, hcv ab+) at screening 6. participants with signs of autoimmune diseases 7. participants with history of myocarditis 8. participants on any immune modulating or investigational drug 9. pregnant or breastfeeding female

Keywords: hiv reservoir perinatally hiv infected children vaccine